European Monitoring Centre for Drugs and Drug Addiction. (2014) Report on the risk assessment of 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide in the framework of the Council Decision on new psychoactive substances. Luxembourg: Office for Official Publications of the European Communities.
Preview | Title | Contact |
---|---|---|
|
PDF (Risk assessment of 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide)
- Published Version
547kB |
This report presents the data and findings of the risk assessment on the new psychoactive substance, 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide, that was conducted by the Scientific Committee of the EMCDDA. Concerns over this synthetic opioid in the European Union led to an assessment of the health and social risks posed by the substance in April 2014.
AH-7921 is a synthetic opioid analgesic with a unique chemical structure. AH-7921 has appeared recently on the illicit drug market typically as a white powder.
Another name of AH-7921 (7), used by Internet suppliers/retailers selling the substance, user websites and in the popular media, is ‘doxylam’. It is important to note that ‘doxylam’ can easily be confused with ‘doxylamine’ — sometimes abbreviated also as ‘doxylam’
B Substances > New (novel) psychoactive substances > Synthetic opioids
E Concepts in biomedical areas > Pharmacology and toxicology
J Health care, prevention, harm reduction and treatment > Risk and needs assessment > Risk assessment
L Social psychology and related concepts > Legal availability or accessibility
MM-MO Crime and law > Substance use laws > Drug laws
VA Geographic area > Europe
Repository Staff Only: item control page